Clinical utility of anti-carbamylated antibody in rheumatoid arthritis female patients: Emerging predictive value compared to anti-cyclic citrullinated peptide and rheumatoid factor

Aim of the work: To evaluate the frequency of anti-carbamylated protein (anti-CarP) antibodies positivity in female rheumatoid arthritis (RA) patients; to study their association with different disease aspects clinically and radiologically and to assess their potential predictive role of RA disease...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Ahmed E. Hafez, Aya H. Abdelazeem, Mohamed A. Abdelhakeem, Ayman F. Darwesh
Formato:	article
Lenguaje:	EN
Publicado:	Elsevier 2022
Materias:	Rheumatoid arthritis Activity Structural damage Anti-carbamylated protein Anti-cyclic citrullinated peptide Rheumatoid factor Immunologic diseases. Allergy RC581-607
Acceso en línea:	https://doaj.org/article/fb792071ebe0407bb20b160d0378ba99
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:fb792071ebe0407bb20b160d0378ba99
record_format	dspace
spelling	oai:doaj.org-article:fb792071ebe0407bb20b160d0378ba992021-11-26T04:24:25ZClinical utility of anti-carbamylated antibody in rheumatoid arthritis female patients: Emerging predictive value compared to anti-cyclic citrullinated peptide and rheumatoid factor1110-116410.1016/j.ejr.2021.11.001https://doaj.org/article/fb792071ebe0407bb20b160d0378ba992022-04-01T00:00:00Zhttp://www.sciencedirect.com/science/article/pii/S1110116421000983https://doaj.org/toc/1110-1164Aim of the work: To evaluate the frequency of anti-carbamylated protein (anti-CarP) antibodies positivity in female rheumatoid arthritis (RA) patients; to study their association with different disease aspects clinically and radiologically and to assess their potential predictive role of RA disease compared to other autoantibodies. Patients and methods: Fifty-one RA female patients and 44 age-matched controls were studied. Duration of morning stiffness, disease activity score (DAS28) and health assessment questionnaire (HAQ) were assessed. Laboratory investigations included acute phase reactants, rheumatoid factor (RF), anti-cyclic citrullinated peptide (anti-CCP) and anti-CarP antibodies. Conventional radiography of both hands and feet was performed and assessed by a simple erosion narrowing score (SENS). All patients were evaluated by ultrasound 7 (US7) score. Results: The mean age of patients was 46.9 ± 8.6 years with disease duration of 6.2 ± 5.3 years. Anti-CarP antibody was positive in 52% and 54.5% of patients seronegative for anti-CCP and RF respectively. RF was positive in 40 (78.4), anti-CCP was positive in 26(51%), and anti-CarP in 21 (41.2%) patients. Anti-CarP antibodies were significantly associated with radiological damage, DAS28, HAQ and acute phase reactants. The sensitivity and specificity were 41.2% and 88.6%, respectively for anti-CarP, 51% and 93.2% for anti-CCP and 78.4% and 90.9% for RF to diagnose RA. Conclusions: An association between anti-CarP antibody positivity and the disease activity, severity, structural damage and hence poor disease outcome has been demonstrated. Testing anti-CarP antibodies could be a useful marker for the assessment of disease activity as well as the expectation of prognosis in RA patients.Ahmed E. HafezAya H. AbdelazeemMohamed A. AbdelhakeemAyman F. DarweshElsevierarticleRheumatoid arthritisActivityStructural damageAnti-carbamylated proteinAnti-cyclic citrullinated peptideRheumatoid factorImmunologic diseases. AllergyRC581-607ENEgyptian Rheumatologist, Vol 44, Iss 2, Pp 175-179 (2022)
institution	DOAJ
collection	DOAJ
language	EN
topic	Rheumatoid arthritis Activity Structural damage Anti-carbamylated protein Anti-cyclic citrullinated peptide Rheumatoid factor Immunologic diseases. Allergy RC581-607
spellingShingle	Rheumatoid arthritis Activity Structural damage Anti-carbamylated protein Anti-cyclic citrullinated peptide Rheumatoid factor Immunologic diseases. Allergy RC581-607 Ahmed E. Hafez Aya H. Abdelazeem Mohamed A. Abdelhakeem Ayman F. Darwesh Clinical utility of anti-carbamylated antibody in rheumatoid arthritis female patients: Emerging predictive value compared to anti-cyclic citrullinated peptide and rheumatoid factor
description	Aim of the work: To evaluate the frequency of anti-carbamylated protein (anti-CarP) antibodies positivity in female rheumatoid arthritis (RA) patients; to study their association with different disease aspects clinically and radiologically and to assess their potential predictive role of RA disease compared to other autoantibodies. Patients and methods: Fifty-one RA female patients and 44 age-matched controls were studied. Duration of morning stiffness, disease activity score (DAS28) and health assessment questionnaire (HAQ) were assessed. Laboratory investigations included acute phase reactants, rheumatoid factor (RF), anti-cyclic citrullinated peptide (anti-CCP) and anti-CarP antibodies. Conventional radiography of both hands and feet was performed and assessed by a simple erosion narrowing score (SENS). All patients were evaluated by ultrasound 7 (US7) score. Results: The mean age of patients was 46.9 ± 8.6 years with disease duration of 6.2 ± 5.3 years. Anti-CarP antibody was positive in 52% and 54.5% of patients seronegative for anti-CCP and RF respectively. RF was positive in 40 (78.4), anti-CCP was positive in 26(51%), and anti-CarP in 21 (41.2%) patients. Anti-CarP antibodies were significantly associated with radiological damage, DAS28, HAQ and acute phase reactants. The sensitivity and specificity were 41.2% and 88.6%, respectively for anti-CarP, 51% and 93.2% for anti-CCP and 78.4% and 90.9% for RF to diagnose RA. Conclusions: An association between anti-CarP antibody positivity and the disease activity, severity, structural damage and hence poor disease outcome has been demonstrated. Testing anti-CarP antibodies could be a useful marker for the assessment of disease activity as well as the expectation of prognosis in RA patients.
format	article
author	Ahmed E. Hafez Aya H. Abdelazeem Mohamed A. Abdelhakeem Ayman F. Darwesh
author_facet	Ahmed E. Hafez Aya H. Abdelazeem Mohamed A. Abdelhakeem Ayman F. Darwesh
author_sort	Ahmed E. Hafez
title	Clinical utility of anti-carbamylated antibody in rheumatoid arthritis female patients: Emerging predictive value compared to anti-cyclic citrullinated peptide and rheumatoid factor
title_short	Clinical utility of anti-carbamylated antibody in rheumatoid arthritis female patients: Emerging predictive value compared to anti-cyclic citrullinated peptide and rheumatoid factor
title_full	Clinical utility of anti-carbamylated antibody in rheumatoid arthritis female patients: Emerging predictive value compared to anti-cyclic citrullinated peptide and rheumatoid factor
title_fullStr	Clinical utility of anti-carbamylated antibody in rheumatoid arthritis female patients: Emerging predictive value compared to anti-cyclic citrullinated peptide and rheumatoid factor
title_full_unstemmed	Clinical utility of anti-carbamylated antibody in rheumatoid arthritis female patients: Emerging predictive value compared to anti-cyclic citrullinated peptide and rheumatoid factor
title_sort	clinical utility of anti-carbamylated antibody in rheumatoid arthritis female patients: emerging predictive value compared to anti-cyclic citrullinated peptide and rheumatoid factor
publisher	Elsevier
publishDate	2022
url	https://doaj.org/article/fb792071ebe0407bb20b160d0378ba99
work_keys_str_mv	AT ahmedehafez clinicalutilityofanticarbamylatedantibodyinrheumatoidarthritisfemalepatientsemergingpredictivevaluecomparedtoanticycliccitrullinatedpeptideandrheumatoidfactor AT ayahabdelazeem clinicalutilityofanticarbamylatedantibodyinrheumatoidarthritisfemalepatientsemergingpredictivevaluecomparedtoanticycliccitrullinatedpeptideandrheumatoidfactor AT mohamedaabdelhakeem clinicalutilityofanticarbamylatedantibodyinrheumatoidarthritisfemalepatientsemergingpredictivevaluecomparedtoanticycliccitrullinatedpeptideandrheumatoidfactor AT aymanfdarwesh clinicalutilityofanticarbamylatedantibodyinrheumatoidarthritisfemalepatientsemergingpredictivevaluecomparedtoanticycliccitrullinatedpeptideandrheumatoidfactor
_version_	1718409942808920064

Clinical utility of anti-carbamylated antibody in rheumatoid arthritis female patients: Emerging predictive value compared to anti-cyclic citrullinated peptide and rheumatoid factor

Ejemplares similares